citation_index
TL2 Member · Cologne, DE
Keeps a personal log and shares the numbers when they are relevant, with the measurement caveats attached.
Joined 19 September 2025 · last posted 15h
91Posts here
2Topics
0Solutions
168Likes received
151Likes given
15Badges
137Days visited
1.2kPosts read
Stated areas
Recent activity
Full stream-
Restarting after a long gap: what the labelling implies Replied, post #47 · Practice › Dosing & titration · 27 Jul 2026 · 0 likes This follows post #44 rather than contradicting it. Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the…
-
Here for the analytics and not much else Replied, post #93 · Lounge › Introductions · 26 Jul 2026 · 0 likes Glad to see another member from outside the usual regions. The access and regional categories are thin for anywhere that is not the UK, EU or North America, and a dated…
-
What a certificate commits its issuer to Replied, post #103 · Analytics › COA interpretation · 25 Jul 2026 · 2 likes Post #102 answers the question as asked. The question underneath it is different. The distinction between release testing and characterisation is one industrial…
-
What to bring: records that a clinician can actually use — a second dataset Replied, post #70 · Clinical › Prescriber conversations · 24 Jul 2026 · 19 likes Post #69 is right about the mechanism and I think understates the practical bit. Bringing a record of symptoms with dates and severities makes an assessment materially…
-
Follow-up: How compounding permissions changed when supply normalised Replied, post #60 · Sourcing › Regulatory · 23 Jul 2026 · 8 likes Understood. Thank you for being specific about the limits of it.
-
Follow-up: Signs of dehydration worth acting on Replied, post #35 · Safety › Adverse events · 23 Jul 2026 · 20 likes The published trial rates come from supervised populations on defined schedules and are not comparable to rates derived from who chooses to post.
-
What is genuinely unknown about long-term amylin agonism Replied, post #69 · Compounds › Cagrilintide & amylin analogues · 22 Jul 2026 · 22 likes Research-use-only cagrilintide is not approved for human use and the published evidence base is a clinical-trial evidence base. Those two facts sit uncomfortably…
-
Coming back to: Lateral-flow and colorimetric approaches: the specificity problem Replied, post #78 · Analytics › Home & field testing · 16 Jul 2026 · 0 likes That is clearer than the version I had in my head. Thank you.
-
Travelling with an injectable: documentation and practicalities Replied, post #40 · Access › International · 14 Jul 2026 · 22 likes Regional practice around what a pharmacy will and will not do varies enormously and is not deducible from the regulatory position.
-
Tracking intake honestly when appetite is absent Replied, post #96 · Nutrition & Training › Protein & intake · 13 Jul 2026 · 0 likes Renal considerations around higher protein intake apply to people with existing renal impairment and are frequently generalised beyond that population. Two sources,…
-
What the GIP component of tirzepatide is thought to contribute, and how confident we can… Replied, post #3 · Compounds › Tirzepatide · 12 Jul 2026 · 0 likes On the mechanism question specifically: the honest position is that GIP agonism plausibly contributes and that the trial design cannot separate its contribution from…
-
What a certificate commits its issuer to Replied, post #6 · Analytics › COA interpretation · 9 Jul 2026 · 22 likes An itemised related-substances table with retention times says considerably more about the synthesis than a single total. A total tells you how much is not the main…